The TB Immunology research group conducts basic research aiming to enhance our understanding of the complex host-pathogen interaction in TB with a strong focus on human immunity to TB. We also carry out translational and clinical research projects that contribute to the development of improved TB diagnosis, vaccine and host-directed therapies. Our research activities are interlaced across three complementary pillars:
- TB protective immunity
- Immunoregulation of Mtb physiology
- Immunodiagnosis of TB
Human immune responses are in many instances efficient enough to prevent infection by Mycobacterium tuberculosis (Mtb). Mtb virulence relies notably on its capacity to escape the bactericidal functions of macrophages despite potentiation by NK and T cell-derived cytokines. To support the development of host-directed therapies and new vaccines against TB, we aim to understand the interplays between host-pathogen genetic traits, co-infections and environmental factors that hamper immune functions and pave the way for active TB disease.
In vitro, ex vivo and in clinico evidence are pointing towards substantial phenotypic heterogeneity across Mtb populations that can be linked to virulence traits such persistence, tolerance, reactivation and transmission. Using clinical Mtb isolates and cellular models of infection, encompassing macrophage and in vitro granuloma, we aim to dissect the contribution of individual immune cell types and their products that would favor or prevent Mtb physiological variation at the population level and influence aforementioned Mtb virulence traits.
Non-sputum based biomarkers diagnostic tools are required to overcome the paucibacillary nature and extra-pulmonary propensity of TB/HIV co-infection and childhood TB. We previously demonstrated unprecedented accuracy of an immunodiagnosis approach measuring phenotypic markers of Mtb-specific T cells by flow cytometry. We are aiming to refine and develop this assay towards a point-of-care test.
Selected ProjectsAll Projects
Latest PublicationsAll Publications
Osei-Wusu S et al. Macrophage susceptibility to infection by Ghanaian Mycobacterium tuberculosis complex lineages 4 and 5 varies with self-reported ethnicity. Front Cell Infect Microbiol. 2023;13:1163993. DOI: 10.3389/fcimb.2023.1163993
Zwyer M et al. Back-to-Africa introductions of Mycobacterium tuberculosis as the main cause of tuberculosis in Dar es Salaam, Tanzania. PLoS Pathog. 2023;19(4):e1010893. DOI: 10.1371/journal.ppat.1010893
Hiza H et al. CD38 expression by antigen-specific CD4 t cells is significantly restored 5 months after treatment initiation independently of sputum bacterial load at the time of tuberculosis diagnosis. Front Med. 2022;9:821776. DOI: 10.3389/fmed.2022.821776
Vaezipour N et al. Towards accurate point-of-care tests for tuberculosis in children. Pathogens. 2022;11(3):327. DOI: 10.3390/pathogens11030327
Xu Z.M et al. Using population-specific add-on polymorphisms to improve genotype imputation in underrepresented populations. PLoS Comput Biol. 2022;18(1):e1009628. DOI: 10.1371/journal.pcbi.1009628
Arbués A, Schmidiger S, Kammüller M, Portevin D. Extracellular matrix-induced GM-CSF and hypoxia promote immune control of Mycobacterium tuberculosis in human in vitro granulomas. Front Immunol. 2021;12:727508. DOI: 10.3389/fimmu.2021.727508
Hiza H et al. Case-control diagnostic accuracy study of a non-sputum CD38-based TAM-TB test from a single milliliter of blood. Sci Rep. 2021;11(1):13190. DOI: 10.1101/2021.03.10.21253246